Biopharma Industry Eyes 2025 Rebound, Navigates Uncertain Policy Landscape Under New Administration
Biopharma anticipates a 2025 rebound despite policy uncertainty under the new administration, particularly regarding drug pricing and the Inflation Reduction Act’s impact. Investor focus remains on Medicare negotiations and potential legislative changes, as companies navigate patent expirations and seek new growth opportunities.